ArticleJournal of cellular and molecular medicine2018
Identification of Sox6 as a regulator of pancreatic cancer development.
Article in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- SOX6 is expressed in various cell lineages in the developing mouse heart and contributes to proper valvuloseptal development.Anatomical record (Hoboken, N.J. : 2007) · 2026Article
- Molecular signature of immune-related new survival predictions for subtype of renal cell carcinomas.Translational andrology and urology · 2024Article
- Cisplatin-based miRNA delivery strategy inspired by the circCPNE1/miR-330-3p pathway for oral squamous cell carcinoma.Acta pharmaceutica Sinica. B · 2024Article
- Transcriptional repression of the oncofetal LIN28B gene by the transcription factor SOX6.Scientific reports · 2024Article
- SOX on tumors, a comfort or a constraint?Cell death discovery · 2024Review
- Propranolol inhibits EMT and metastasis in breast cancer through miR-499-5p-mediated Sox6.Journal of cancer research and clinical oncology · 2024Article
- Clinical implications and genetical insights of SOX6 expression in acute myeloid leukemia.Journal of cancer research and clinical oncology · 2023Article
- Association between miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444 polymorphisms and the risk of esophageal carcinoma: A case-control study.Cancer medicine · 2022Article
- Corrigendum.Journal of cellular and molecular medicine · 2022Article
- NMilitary Medical Research · 2022Article
- Stanniocalcin-2 promotes cell EMT and glycolysis via activating ITGB2/FAK/SOX6 signaling pathway in nasopharyngeal carcinoma.Cell biology and toxicology · 2022Article
- MicroRNA-mediated regulation of key signaling pathways in hepatocellular carcinoma: A mechanistic insight.Frontiers in genetics · 2022Review
- Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.Cancer discovery · 2021Article
- Inhibition of lncRNA MAAT Controls Multiple Types of Muscle Atrophy by cis- and trans-Regulatory Actions.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- lncRNA PART1, manipulated by transcriptional factor FOXP2, suppresses proliferation and invasion in ESCC by regulating the miR‑18a‑5p/SOX6 signaling axis.Oncology reports · 2021Observational
- The Role of Noncoding RNAs in the Regulation of Anoikis and Anchorage-Independent Growth in Cancer.International journal of molecular sciences · 2021Review
- Identification of SOX6 and SOX12 as Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma: A Retrospective Study Based on TCGA Database.Disease markers · 2021Article
- SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis.Molecular cancer research : MCR · 2020Article
- The Epithelial-to-Mesenchymal Transition (EMT) in Development and Cancer.Annual review of cancer biology · 2020Article
- miRNA‑342 suppresses renal interstitial fibrosis in diabetic nephropathy by targeting SOX6.International journal of molecular medicine · 2020Article
Corrections and comments
- Erratum issuedCorrigendum.2022
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is an aggressive malignancy associated with a poor prognosis and low responsiveness to chemotherapy and radiotherapy. Most patients with PC have metastatic disease at diagnosis, which partly accounts for the high mortality from this disease. Here, we explored the role of the transcription factor sex-determining region Y-box (Sox) 6 in the invasiveness of PC cells. We showed that Sox6 is down-regulated in patients with PC in association with metastatic disease. Sox6 overexpression suppressed PC cell proliferation and migration in vitro and tumour growth and liver metastasis in vivo. Sox6 inhibited epithelial-mesenchymal transition (EMT), and Akt signalling. Sox6 was shown to interact with the promoter of Twist1, a helix-loop-helix transcription factor involved in the induction of EMT, and to modulate the expression of Twist1 by recruiting histone deacetylase 1 to the promoter of the Twist1 gene. Twist1 overexpression reversed the effect of Sox6 on inhibiting EMT, confirming that the effect of Sox6 on suppressing tumour invasiveness is mediated by the modulation of Twist1 expression. These results suggest a novel mechanism underlying the aggressive behaviour of PC cells and identify potential therapeutic targets for the treatment of PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.